Expression and Influence of Matrix Metalloproteinase-9/Tissue Inhibitor of Metalloproteinase-1 and Vascular Endothelial Growth Factor in Diabetic Foot Ulcers

被引:25
|
作者
Li, Gongchi [1 ]
Zou, Xinhua [2 ]
Zhu, Youpeng [2 ]
Jing, Zhang [2 ]
Zhou, Lijun [2 ]
Wang, Dan [2 ]
Li, Binghui [2 ]
Chen, Zhenbing [1 ,3 ]
机构
[1] Huazhong Univ Sci & Technol, Wuhan Union Hosp, Wuhan, Hubei, Peoples R China
[2] Huazhong Univ Sci & Technol, Liyuan Hosp Tongji Med Coll, Wuhan, Hubei, Peoples R China
[3] Huazhong Univ Sci & Technol, Wuhan Union Hosp, No 1277 Jlefang Ave, Wuhan, Hubei, Peoples R China
来源
关键词
diabetic foot ulcers (DFUs); wound infection; matrix metalloproteinase-9 (MMP9); tissue inhibitor of metalloproteinases-1 (TIMP1); vascular endothelial growth factor (VEGF); TISSUE INHIBITORS; MATRIX-METALLOPROTEINASE-9; ANGIOGENESIS; INFECTION; INFLAMMATION; DIAGNOSIS; MMPS; SKIN;
D O I
10.1177/1534734617696728
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
A high matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 (MMP9/TIMP1) ratio is associated with poor ulcer healing, yet how the ratio of MMP9/TIMP1 changes in diabetic foot ulcers (DFUs) with infection and how these changes may affect wound healing remain unclear. Therefore, the objective of this investigation was to explore relationships among the MMP9/TIMP1 ratio, infection, and DFUs. After being informed of the details of this study, 32 patients signed consent forms. Skin biopsies were performed for all patients. Wound tissues were obtained from all patients with wounds, and healthy skin samples were collected from patients without wounds during orthopedic surgery. Microbial cultures were obtained using the samples from diabetic patients with wounds. All patients were divided into 4 groups according to colony-forming units (CFUs) per gram of tissue (> 1 x 10(6) or < 1 x 10(6)): group A (diabetic wounds with high quantities of bacteria), group B (diabetic wounds with low quantities of bacteria), group C (diabetic patients without wounds), and group D (nondiabetic patients with wounds). In addition, the biopsies were evaluated by both reverse transcription-quantitative polymerase chain reaction and Western blotting to assess the levels of MMP9, TIMP1, and vascular endothelial growth factor (VEGF). The results show that for both mRNA and protein, expression of MMP9 (fold change 1.14 +/- 0.12 vs 0.60 +/- 0.08 vs 0.39 +/- 0.09 vs 0.13 +/- 0.06, P <.01) decreased, whereas that of TIMP1 (1.01 +/- 0.09 vs 2.86 +/- 0.85 vs 4.88 +/- 0.83 vs 7.29 +/- 1.55, P <.01) and VEGF (1.01 +/- 0.22 vs 3.55 +/- 0.97 vs 5.72 +/- 0.55 vs 6.92 +/- 1.55, P <.01) increased from group A to group D. These results suggest that an increase in the MMP9/TIMP1 ratio in infected DFUs may induce a decrease in VEGF expression.
引用
收藏
页码:6 / 13
页数:8
相关论文
共 50 条
  • [31] Matrix metalloproteinase and tissue inhibitor of metalloproteinase expression in diabetic and venous ulcers
    Jude, EB
    Rogers, AA
    Oyibo, SO
    Armstrong, DG
    Boulton, AJM
    DIABETOLOGIA, 2001, 44 : A3 - A3
  • [32] Clinical Significance of the Measurements of Serum Matrix Metalloproteinase-9 and Its Inhibitor (Tissue Inhibitor of Metalloproteinase-1) in Patients With Pancreatic Cancer Metalloproteinase-9 as an Independent Prognostic Factor
    Mroczko, Barbara
    Lukaszewicz-Zajac, Marta
    Wereszczynska-Siemiatkowska, Urszula
    Groblewska, Magdalena
    Gryko, Mariusz
    Kedra, Boguslaw
    Jurkowska, Grazyna
    Szmitkowski, Maciej
    PANCREAS, 2009, 38 (06) : 613 - 618
  • [33] Ratios of activated matrix metalloproteinase-9 to tissue inhibitor of matrix metalloproteinase-1 in wound fluids are inversely correlated with healing of pressure ulcers
    Ladwig, GP
    Robson, MC
    Liu, R
    Kuhn, MA
    Muir, DF
    Schultz, GS
    WOUND REPAIR AND REGENERATION, 2002, 10 (01) : 26 - 37
  • [34] IMBALANCE BETWEEN TISSUE INHIBITOR OF METALLOPROTEINASE-1 AND MATRIX METALLOPROTEINASE-9 AFTER CARDIOPULMONARY RESUSCITATION
    Li Jingsha
    Zhong Jingquan
    Zeng Qixian
    Liu Hongzhen
    Meng Xianglin
    Liu Donglin
    Su Guoying
    Zhang Yun
    HEART, 2011, 97
  • [35] Imbalanced matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 activities in patients with thromboangiitis obliterans
    Dellalibera-Joviliano, Renata
    Jacob-Ferreira, Anna L. B.
    Joviliano, Edwaldo Edner
    Tanus-Santos, Jose E.
    Evora, Paulo R. B.
    VASCULAR MEDICINE, 2012, 17 (02) : 73 - 78
  • [36] Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension: Relationship to cardiovascular risk and treatment
    Tayebjee, MH
    Nadar, SK
    Blann, AD
    Beevers, DG
    MacFadyen, RJ
    Lip, GY
    AMERICAN JOURNAL OF HYPERTENSION, 2004, 17 (05) : 23A - 23A
  • [37] Impact of losartan and angiotensin lion the expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in rat vascular smooth muscle cells
    Guo, Yan-Song
    Wu, Zong-Gui
    Yang, Jun-Ke
    Chen, Xen-Jing
    MOLECULAR MEDICINE REPORTS, 2015, 11 (03) : 1587 - 1594
  • [38] Role of matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1 and hyaluronic acid in acute pyelonephritis
    Kavaz, A.
    Ekim, M.
    Ikinciogullari, A.
    Guloglu, D.
    Ozcakar, Z. B.
    Yalcinkaya, F.
    PEDIATRIC NEPHROLOGY, 2008, 23 (09) : 1701 - 1701
  • [39] Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in diagnosis of pleural effusion of malignant origin
    Fiorelli, Alfonso
    Ricci, Serena
    Feola, Antonia
    Mazzella, Antonio
    D'Angelo, Luigi
    Santini, Mario
    Di Domenico, Marina
    Di Carlo, Angelina
    INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY, 2016, 22 (04) : 411 - 418
  • [40] Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 and-2 in type 2 diabetes
    Tayebjee, MH
    Lim, HS
    MacFadyen, R
    Lip, GYH
    DIABETES CARE, 2004, 27 (08) : 2049 - 2051